Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study

De Pauw, 2008, Clin Infect Dis, 46, 1813, 10.1086/588660

Cornely, 2008, Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death, Clin Infect Dis, 46, 1626, 10.1086/587177

Trotti, 2000, Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy, Int J Radiat Oncol Biol Phys, 47, 13, 10.1016/S0360-3016(99)00559-3

Shen, 2013, Posaconazole vs. fluconazole as invasive fungal infection prophylaxis in China: a multicenter, randomized, open-label study, Int J Clin Pharmacol Ther, 51, 738, 10.5414/CP201880

Aperis, 2011, Posaconazole: a new antifungal weapon, Rev Recent Clin Trials, 6, 204, 10.2174/157488711796575595

Freifeld, 2011, Clinical practice guideline for the use of antimicrobial agents in neutropenia patients with cancer: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis, 52, e56, 10.1093/cid/cir073

Neofytos, 2009, Epidemiology and outcome of invasive fun#infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter Prospective Antifungal Therapy (PATH) Alliance registry, Clin Infect Dis, 48, 265, 10.1086/595846

Raad, 2006, Safety of long-term oral term oral posaconazole use in the treatment of refractory invasive fungal invasive fungal infections, Clin Infect Dis, 42, 1726, 10.1086/504328

Hoffman, 2002, Review of the safety and efficacy of voriconazole, Expert Opin Investing Drugs, 11, 409, 10.1517/13543784.11.3.409

Jansen, 2010, Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands, Ann Hematol, 89, 919, 10.1007/s00277-010-0939-8

O'Sullivan, 2012, Cost effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease, Am J Health Syst Pharm, 69, 149, 10.2146/ajhp110149

Michallet, 2011, Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system, J Med Econ, 14, 28, 10.3111/13696998.2010.542393

Antosz, 2017, Comparison of posaconazole versus voriconazole in the induction of acute myeloid leukemia: impact on cost, safety, and efficacy, Biol Blood Marrow Transplant, 23, S18, 10.1016/j.bbmt.2016.12.505